focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
PYC have recently had new collabs from Bicycle, who raised appox $240m.
They helped with Cellcentric with CCS1477 ( now inobrodib )and they have just raised approx $20m and had fast track orphan status from FDA.
Numab secured $110m funding in 2021.
You could hope that a fraction of those $ or £ raised ( at least ) could come PYC's way to help with projects either already started or in the future from these companies
There could be a big queue for who might we want to aquire PYC some f whom are already cashed up major clients like Bicycle and Merck
I guess we will find out next week by the price action, if anymore big trades pop up then there is definitely something afoot. The price rose long before that 80k popped up so my guess is we have very good news coming and someone in the know is loading up.
Billy, i wish i could share your enthusiasm on this point, however, if "someone" is building a stake, we know from previous times, that a big buyer does not always report a TR1 themselves, and it only comes to light after JM does a 6 month check of the share register. This is how we know Gary Marshall is over 3%, as nothing was reported before, and then after the check, his name appears. I guess this prognosis is different if a II is involved? I would dearly love to see a II or a HNWI be involved here BTW.
My guess is someone is positioning themselves to takeover PYC whilst the MKT CAP is cheap (3.5m) They know something and they want it. I expect to see more nice buys on Monday and a TR1 next week revealing who it is. If my hunch is correct this will multibag just on suspicion alone. I myself will be buying more on Monday. GLA
Further gains for next week.
Expecting sp to surpass 3 early week.
Exciting times for this company, transformatiol
Acker
Kid
Agreed 2.18% it is, still huge
From PYC website regarding PYC A.I applications
Personalised Dosing Tool Development
Data Identification
Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria
AI & Machine Learning
Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy
LONDON, Sept 22 (Reuters) - Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.
Human studies are the most expensive and time-consuming part of drug development as it can take years to recruit patients and trial new medicines in a process that can cost over a billion dollars from the discovery of a drug to the finishing line.
Pharmaceutical companies have been experimenting with AI for years, hoping machines can discover the next blockbuster drug. A few compounds picked by AI are now in development, but those bets will take years to play out.
Reuters interviews with more than a dozen pharmaceutical company executives, drug regulators, public health experts and AI firms show, however, that the technology is playing a sizeable and growing role in human drug trials.
And just for your information I sold 20000 at 4.27 for 2.65 happy to send you a picture if you reallly want me to xx
Https://www.reuters.com/technology/big-pharma-bets-ai-speed-up-clinical-trials-2023-09-22/
Maybe they are both does happen . I must have brought to sell , plus what does it matter ,
Strange as you had never bought nor posted on PYC since you joined LSE
They are buys as one is mine
I’ll claim they are sells as one was mine
Newuncle, new COO or any other BOD can not buy as in closed period?
Also more details on these
further expansion and diversification of its client base;
· expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and
· exploration of opportunities around its personalised oncology software offering.
The biggest plus for me is that Merck have now recommenced and that was pretty much the reason for the temporary loss of revenue from Jan to April ( explained in the TUs)
Merck spend €500k annually
What ever the % it appears it was deliberately below the 3% threshold? However the booked cost of £80k seems very exact.?
Sienna
The numbers for year ended June 2023 are known (see trading statment in April/may 2023)
Its the outlook statement and ambition for CURRENt 2023 and 2024 year which will be interesting given the momentum already achieved ßince July
I make it 2.18%
2962703 is 2.18% of 135470000 shares in issue?
There was a delayed buy which filled during that time period Kidlington
The grey trade at the end of the day
May be the new coo has gone in big?
My maths suggests buyer bought 2.7% of the company yesterday?
I am also sure the 2.65 are buys to?
Anyone else notice that as sells were going through between 1300 and 1600, the price kept on moving up? Not sure if data on L2 reflected this? Maybe it was delayed buys on the book & not showing, but it looked odd.
They are buys and not sure why some people would claim otherwise